MIAMI, FL / ACCESS Newswire / November 12, 2025 / iTolerance, Inc. (“iTolerance” or the “Company”), an early-stage privately-held biotechnology company focused on the development of innovative regenerative medicines, today announced that Anthony Japour, Chief Executive Officer and President of iTolerance, received the Research & Developer of the Year Award at the recently held BioFlorida Innovation Conference in Miami, FL.
“We are honored that BioFlorida has recognized our team’s work and the potential of our technology to transform the Type 1 diabetes treatment landscape. Receiving the Research & Developer of the Year Award from BioFlorida is a humbling recognition of the dedication of the entire iTolerance team and our collaborators. At iTolerance, we are driven by a singular purpose; to advance therapies that enable life-changing therapies without the need for life-long immunosuppression. This award reinforces our conviction that innovation backed by science can bring real hope to patients who currently face limited options. We look forward to building on this momentum and accelerating our journey forward,” commented Anthony Japour, CEO of iTolerance.
This accolade underscores iTolerance’s commitment to innovation, patient focused development and driving its pipeline forward to clinical translation. Looking ahead, the Company remains focused on advancing its lead programs toward first-in-human clinical studies and broader applications of its immune tolerance platform.
About iTolerance, Inc.
iTolerance is a regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without requiring life-long immunosuppression. Leveraging its proprietary biotechnology-derived Streptavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic cadaveric and stem cell-derived pancreatic islets to potentially cure Type 1 diabetes. Utilizing iTOL-100 to induce local immune tolerance, the Company is developing its lead indication as a potential cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the Company is developing iTOL-201 for treating liver failure by utilizing hepatocytes and iTOL-401 as a nanoparticle formulation for large organ transplants without the need for life-long immunosuppression. For more information, please visit itolerance.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.
All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, anticipated levels of revenues, future national or regional economic and competitive conditions, and difficulties in developing the Company’s platform technology. Consequently, forward-looking statements should be regarded solely as the Company’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. The Company cannot guarantee future results, events, levels of activity, performance or achievements. The Company does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.
Investor Contact
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
iTolerance@jtcir.com
Media Contact
Susan Roberts
T:202.779.0929
sr@roberts-communications.com
SOURCE: iTolerance, Inc.
View the original press release on ACCESS Newswire
